Role of β-Adrenergic Receptor Subtypes in Lipolysis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In vitro lipolysis stimulated by low (-)-isopre-naline concentrations (≤30 nM) in epididymal white adipo-cytes from Sprague-Dawley rats was inhibited at least 60–80% by the specific β1-antagonists LK 204-545 and CGP 20712A (1 μM), suggesting that at these low (10 nM) concentrations of (-)-isoprenaline lipolysis was primarily (80%) but not solely mediated via β1-adrenergic receptors. Low concentrations (100 nM) of (-)-noradrenaline and formoterol also confirmed a role for β1-adrenergic receptors in mediating lipolysis at low concentrations of these agonists. At higher agonist concentrations, β3-adrenergic receptors were fully activated and were the dominant β-adrenergic receptor subtype mediating the maximum lipolytic response, and the maximum response was not affected by the β1-antagonists, demonstrating that the β3-receptor is capable of inducing maximum lipolysis on its own. Studies of lipolysis induced by the relatively β2-selective agonist formoterol in the presence of β1-blockade (1 μM CGP 20712A) demonstrated the inability of the β2-selective antagonist ICI 118-551 to inhibit the residual lipolysis at concentrations of ICI 118-551 ≤ 1 μM. Higher concentrations of ICI 118-551 inhibited the residual formoterol-induced lipolysis competetively, but with low affinity (∼500-fold lower than its β2-adrenergic receptor pA 2, 7.80 ± 0.21), suggesting that formoterol was not acting via β2-adrenergic receptors. These data are consistent with β1-adrenergic receptors playing an important role in lipolysis at physiological but not pharmacological concentrations of catecholamines and that β2-adrenergic receptors play no obvious direct role in mediating β-adrenergic receptor agonist-induced lipolysis in vitro. Finally, racemic-SR 59230A, unlike the pure (S, S)-isomer (a β3-selective antagonist), was found to be a non-selective antagonist at the three β-adrenergic receptor subtypes, showing that the other enantiomers have different selectivity.
- Emorine LJ, Marullo S, Briend-Sutren M-M, et al. Molecular characterisation of the human β 3-adrenergic receptor. Science 1989;245:1118-1121.
- Frielle TJ, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK. Cloning of the cDNA for the human β 1-adrenergic receptor. Proc Natl Acad Sci USA 1987;84:7920-7924.
- Kobilka BK, Dixon RAF, FrielleT, et al. cDNAfor the human β 2-adrenergic receptor: A protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 1987;84:46-50.
- Galitzky J, Carpene C, Bousquet Melou A, Berlan M, Lafontan M. Differential activation of β 1-, β 2-and β 3-adrenoceptors by catecholamines in white and brown adipocytes. Fund Clin Pharmacol 1995;24-331.
- Germack R, Starzec AB, Vassy R, Perret GY. β-adrenoceptor subtype expression and function in rat adipocytes. Br J Pharmacol 1997;120:201-210.
- Granneman JG. Effects of agonist exposure on the coupling of beta1-and beta3-adrenergic receptors to adenylyl cyclase in isolated adipocytes. J Pharmacol Exp Therap 1992;261:638-642.
- Hollenga C, Zaagsma J. Direct evidence for the atypical nature of functional β-adrenoceptors in rat adipocytes. Br J Pharmacol 1989;98:1420-1424.
- Murphy GJ, Kirkham DM, Cawthorne MA, Young PY. Correlation of β 3-adrenoceptor-induced activation of cyclic AMP-dependant protein kinase with activation of lipolysis in rat white adipocytes. Biochem Pharmacol 1993;46:575-581.
- Simard P-M, Atiege C, Maurige P, D'allaire F, Buckowieki LJ. Comparison of the lipolytic effects of norepinephrine and BRL 37344 in rat brown and white adipocytes. Obesity Res 1994;2:424-431.
- Van Liefde L, Van Erman A, Van Witzenburg A, Fraeyman N, Vauquelin G. Species and strain-related differences in the expression and functionality of β-adrenoceptor subtypes in adipose tissue. Archs Int Pharmacodyn Theraps 1994;327:69-86.
- Van Liefde I, Van Witzenberg A, Vauquelin G. Isoproterenol and selective agonists stimulate similar atypical β-adrenoceptors in rat adipocytes. Biocheml Pharmacol 1993;45:974-977.
- Louis SNS, Nero TL, Iakovidis D, Jackman GP, Louis WJ. LK 204-545, a highly selective β 1-adrenoceptor antagonist at human β-adrenoceptors. Eur J Pharmacol 1999;367:431-435.
- Manara L, Badone D, Baroni M, et al. Aryloxypropanolaminotetralins are the first selective antagonists for atypical (β 3) β-adrenoceptors. Pharmacol Comm 1996;253-258.
- Manara L, Badone D, Baroni M, et al. Functional identification of rat atypical adrenoceptors by the first β 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol 1996;117:435-442.
- Nisoli E, Tonello C, Landi M, Carruba O. Functional studies of the first selective β 3-adrenergic receptor antagonist SR 56230A in rat brown adipocytes. Mol Pharmacol 1996;49:7-14.
- Lafontan M, Belan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993;34:1057-1091.
- Tung L, Jackman G, Campbell B, Louis S, Iakovidis D, Louis WJ. Partial agonist activity of celiprolol. J Cardiovasc Pharmacol 1993;21:484-488.
- Van Rossum JM, Hurkmans JATM, Wolters CJJ. Cumulative dose response curves. Arch Int Pharmacodyn Therap 1963;143:299-330.
- Wilson C. The rat lipolytic β-adrenoceptor: Studies using novel β-adrenoceptor agonists. Eur J Pharmacol 1984;100:309-319.
- Garland PB, Randle PJ. Arapid enzymatic assay for glycerol. Nature 1962;196:987.
- Zaborowsky BR, Mcmahan WC, Griffin WA, Norns FH, Ruffolo RRJ. Computerised graphic methods for determining dissociation constants of agonists, partial agonists, and competitive antagonists in isolated smooth muscle preparations. J Pharmacol Methods 1980;4:165-178.
- Mackay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharmacy Pharmacol 1978;30:312-313.
- Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 1959;14:48-58.
- Rang HP. Drug receptors and their function. Nature 1971;231:91-96.
- Cantello BCC, Smith SA. BRL 35135. Drugs Future 1991;16:797-800.
- Cawthorne MA, Sennitt MV, Arch JRS, Smith SA. BRL 35135, a potent and selective atypical β-adrenoceptor agonist. Am J Clin Nutr 1992;55:252S-257S.
- Arch JRS, Kaumann AJ. Beta3 and atypical beta adrenoceptors. Med Res Revs 1993;13:663-729.
- Lafontan M, Bousquet Melou A, Galitzky J, et al. Adrenergic receptors and fat cells: Differential recruitment by physiological amines and homologous regulation. Obesity Resarch 1995;3:507s-513s.
- Iakovidis D, Louis SNS, Rezmann LA, et al. Synthesis and β-adrenoceptor agonist properties of (±)-1-(3',4'-dihydroxyphenoxy)-3-(3”,4”-dimethoxyphenyl) ethylamino-2-propanol hydrochloride, (±)-RO363.HCl, and the (2S)-(-)-isomer. Eur J Medl Chem 1999;34:539-548.
- Mckean J, Macdonald A. Contributions of β-adrenoceptor subtypes to responses to isoprenaline in rat isolated distal colon. J Pharm Pharmacol 1995;47:388-391.
- D'Allaire F, Atiegé C, Mauriége P, Simard PM, Bukowieke LJ. Characterisation of β 1-and β 3-adrenoceptors in intact brown adipocytes of the rat. Br J Pharmacol 1995;114:275-282.
- Role of β-Adrenergic Receptor Subtypes in Lipolysis
Cardiovascular Drugs and Therapy
Volume 14, Issue 6 , pp 565-577
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- selective beta-adrenergic receptor blockade
- white adipocytes
- antagonist selectivity
- Industry Sectors
- Author Affiliations
- 1. Clinical Pharmacology and Therapeutics Unit, Austin and Repatriation Medical Centre, University of Melbourne, Heidelberg, Victoria, Australia
- 2. Clinical Pharmacology and Therapeutics Unit, Austin and Repatriation Medical Centre, University of Melbourne, Heidelberg, Victoria, Australia